186 related articles for article (PubMed ID: 25996761)
1. Synergistically Enhanced Therapeutic Effect of a Carrier-Free HCPT/DOX Nanodrug on Breast Cancer Cells through Improved Cellular Drug Accumulation.
Chen F; Zhao Y; Pan Y; Xue X; Zhang X; Kumar A; Liang XJ
Mol Pharm; 2015 Jul; 12(7):2237-44. PubMed ID: 25996761
[TBL] [Abstract][Full Text] [Related]
2. Nanodrug Formed by Coassembly of Dual Anticancer Drugs to Inhibit Cancer Cell Drug Resistance.
Zhao Y; Chen F; Pan Y; Li Z; Xue X; Okeke CI; Wang Y; Li C; Peng L; Wang PC; Ma X; Liang XJ
ACS Appl Mater Interfaces; 2015 Sep; 7(34):19295-305. PubMed ID: 26270258
[TBL] [Abstract][Full Text] [Related]
3. Integration of phospholipid-hyaluronic acid-methotrexate nanocarrier assembly and amphiphilic drug-drug conjugate for synergistic targeted delivery and combinational tumor therapy.
Li Y; Zhang H; Chen Y; Ma J; Lin J; Zhang Y; Fan Z; Su G; Xie L; Zhu X; Hou Z
Biomater Sci; 2018 Jun; 6(7):1818-1833. PubMed ID: 29785434
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of 10-hydroxycamptothecin with doxorubicin conjugated prodrugs for enhanced anticancer efficacy.
Zhang Y; Xiao C; Li M; Chen J; Ding J; He C; Zhuang X; Chen X
Macromol Biosci; 2013 May; 13(5):584-94. PubMed ID: 23420692
[TBL] [Abstract][Full Text] [Related]
5. Redox-responsive mesoporous selenium delivery of doxorubicin targets MCF-7 cells and synergistically enhances its anti-tumor activity.
Zhao S; Yu Q; Pan J; Zhou Y; Cao C; Ouyang JM; Liu J
Acta Biomater; 2017 May; 54():294-306. PubMed ID: 28267598
[TBL] [Abstract][Full Text] [Related]
6. Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells.
Wang YC; Wang F; Sun TM; Wang J
Bioconjug Chem; 2011 Oct; 22(10):1939-45. PubMed ID: 21866903
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
Zeng X; Morgenstern R; Nyström AM
Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
[TBL] [Abstract][Full Text] [Related]
8. Intracellular target delivery of 10-hydroxycamptothecin with solid lipid nanoparticles against multidrug resistance.
Liu M; Chen D; Wang C; Chen X; Wen Z; Cao Y; He H
J Drug Target; 2015; 23(9):800-5. PubMed ID: 25766079
[TBL] [Abstract][Full Text] [Related]
9. Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.
Chauvier D; Morjani H; Manfait M
Breast Cancer Res Treat; 2002 May; 73(2):113-25. PubMed ID: 12088114
[TBL] [Abstract][Full Text] [Related]
10. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance.
Liu M; Chen D; Mukerabigwi JF; Chen S; Zhang Y; Lei S; Luo S; Wen Z; Cao Y; Huang X; He H
J Drug Target; 2016; 24(5):433-40. PubMed ID: 26422582
[TBL] [Abstract][Full Text] [Related]
11. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
13. Lipid nanoparticles loaded with 10-hydroxycamptothecin-phospholipid complex developed for the treatment of hepatoma in clinical application.
Wei W; Shi SJ; Liu J; Sun X; Ren K; Zhao D; Zhang XN; Zhang ZR; Gong T
J Drug Target; 2010 Aug; 18(7):557-66. PubMed ID: 20131981
[TBL] [Abstract][Full Text] [Related]
14. Triple Block Nanocarrier Platform for Synergistic Cancer Therapy of Antagonistic Drugs.
Surnar B; Jayakannan M
Biomacromolecules; 2016 Dec; 17(12):4075-4085. PubMed ID: 27936725
[TBL] [Abstract][Full Text] [Related]
15. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
[TBL] [Abstract][Full Text] [Related]
16. Nanoscaled poly(L-glutamic acid)/doxorubicin-amphiphile complex as pH-responsive drug delivery system for effective treatment of nonsmall cell lung cancer.
Li M; Song W; Tang Z; Lv S; Lin L; Sun H; Li Q; Yang Y; Hong H; Chen X
ACS Appl Mater Interfaces; 2013 Mar; 5(5):1781-92. PubMed ID: 23410916
[TBL] [Abstract][Full Text] [Related]
17. Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice.
Zhang RX; Zhang T; Chen K; Cheng J; Lai P; Rauth AM; Pang KS; Wu XY
J Vis Exp; 2017 Oct; (128):. PubMed ID: 29053672
[TBL] [Abstract][Full Text] [Related]
18. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
19. pH-Dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells.
Shalviri A; Raval G; Prasad P; Chan C; Liu Q; Heerklotz H; Rauth AM; Wu XY
Eur J Pharm Biopharm; 2012 Nov; 82(3):587-97. PubMed ID: 22995704
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation and Monitoring of the Therapeutic Response of a Dual Targeted Hyaluronic Acid Nanodrug.
Chen M; Zhang W; Yuan K; Bo M; Chen B; Li L; Ma Q; Zhu L; Gao S
Contrast Media Mol Imaging; 2017; 2017():4972701. PubMed ID: 29097925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
